Trial Profile

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teclistamab (Primary) ; Teclistamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man; Pharmacokinetics; Registrational; Therapeutic Use
Acronyms MajesTEC-1
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

25 Apr 2025 Planned End Date changed from 26 Jun 2026 to 28 May 2027.
25 Apr 2025 Planned End Date changed from 26 Jun 2026 to 28 May 2027.
04 Apr 2025 Planned primary completion date changed from 15 Aug 2023 to 30 Nov 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com